-
EP4223785
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4223785
| EP4223785 - PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY-DRUG CONJUGATE, AND USE OF PHARMACEUTICAL COMPOSITION [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 07.07.2023 Database last updated on 24.08.2024 | |
| Former | The international publication has been made Status updated on 08.04.2022 | Most recent event Tooltip | 18.04.2024 | Supplementary search report | published on 15.05.2024 [2024/20] | Applicant(s) | For all designated states Jiangsu Hengrui Pharmaceuticals Co., Ltd. No. 7 Kunlunshan Road Economic and Technological Development Zone Lianyungang, Jiangsu 222047 / CN | For all designated states Shanghai Hengrui Pharmaceutical Co., Ltd. No.279 Wenjing Road Minhang District Shanghai 200245 / CN | [2023/32] | Inventor(s) | 01 /
WANG, Zhiwan Shanghai 200245 / CN | 02 /
WU, Tingting Shanghai 200245 / CN | 03 /
LIU, Xun Shanghai 200245 / CN | [2023/32] | Representative(s) | Dragotti & Associati S.R.L., et al Via Nino Bixio, 7 20129 Milano / IT | [N/P] |
| Former [2023/32] | Pistolesi, Roberto, et al Dragotti & Associati Srl Via Nino Bixio, 7 20129 Milano / IT | Application number, filing date | 21874568.5 | 30.09.2021 | [2023/32] | WO2021CN122031 | Priority number, date | CN20201161863 | 30.09.2020 Original published format: CN202011061863 | CN20211169020 | 13.09.2021 Original published format: CN202111069020 | [2023/32] | Filing language | ZH | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022068914 | Date: | 07.04.2022 | Language: | ZH | [2022/14] | Type: | A1 Application with search report | No.: | EP4223785 | Date: | 09.08.2023 | Language: | EN | [2023/32] | Search report(s) | International search report - published on: | CN | 07.04.2022 | (Supplementary) European search report - dispatched on: | EP | 17.04.2024 | Classification | IPC: | C07K16/30, C12N15/13, A61P35/00, A61K39/395 | [2023/32] | CPC: |
A61K9/19 (EP,KR,US);
A61K47/6849 (EP,KR);
A61K47/6803 (US);
A61K31/4375 (US);
A61K47/26 (EP,KR,US);
A61K47/68037 (EP);
A61K47/6859 (EP);
A61P35/00 (KR,US);
C07K16/28 (EP,US);
C07K16/30 (EP,KR);
A61K2039/505 (EP,KR);
C07K2317/73 (EP);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/32] | Title | German: | PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT ANTIKÖRPER-WIRKSTOFF-KONJUGAT UND VERWENDUNG DER PHARMAZEUTISCHEN ZUSAMMENSETZUNG | [2023/32] | English: | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY-DRUG CONJUGATE, AND USE OF PHARMACEUTICAL COMPOSITION | [2023/32] | French: | COMPOSITION PHARMACEUTIQUE COMPRENANT UN CONJUGUÉ ANTICORPS-MÉDICAMENT, ET UTILISATION DE LA COMPOSITION PHARMACEUTIQUE | [2023/32] | Entry into regional phase | 16.03.2023 | Translation filed | 16.03.2023 | National basic fee paid | 16.03.2023 | Search fee paid | 16.03.2023 | Designation fee(s) paid | 16.03.2023 | Examination fee paid | Examination procedure | 16.03.2023 | Amendment by applicant (claims and/or description) | 16.03.2023 | Examination requested [2023/32] | Fees paid | Renewal fee | 22.08.2023 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [YD]WO2016165762 (GANYMED PHARMACEUTICALS AG [DE], et al); | [Y]WO2020114480 (ZAI LAB SHANGHAI CO LTD [CN], et al); | [Y]WO2020160560 (NOVAROCK BIOTHERAPEUTICS LTD [US]); | [YP]WO2021011885 (UNIV CALIFORNIA [US], et al); |